Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 27;57(6):2393-412.
doi: 10.1021/jm401712t. Epub 2014 Mar 14.

X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases

Affiliations

X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases

Yahira M Báez-Santos et al. J Med Chem. .

Abstract

Structure-guided design was used to generate a series of noncovalent inhibitors with nanomolar potency against the papain-like protease (PLpro) from the SARS coronavirus (CoV). A number of inhibitors exhibit antiviral activity against SARS-CoV infected Vero E6 cells and broadened specificity toward the homologous PLP2 enzyme from the human coronavirus NL63. Selectivity and cytotoxicity studies established a more than 100-fold preference for the coronaviral enzyme over homologous human deubiquitinating enzymes (DUBs), and no significant cytotoxicity in Vero E6 and HEK293 cell lines is observed. X-ray structural analyses of inhibitor-bound crystal structures revealed subtle differences between binding modes of the initial benzodioxolane lead (15g) and the most potent analogues 3k and 3j, featuring a monofluoro substitution at para and meta positions of the benzyl ring, respectively. Finally, the less lipophilic bis(amide) 3e and methoxypyridine 5c exhibit significantly improved metabolic stability and are viable candidates for advancing to in vivo studies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of previously characterized SARS-CoV PLpro inhibitors: (A) hit (1) from a primary HTS from which lead 24 was developed; (B) hit (2) from a primary HTS from which 15g and 15h were developed. The chiral center for the nearly equipotent isomers derived from hit 2 is indicated with an asterisk.
Scheme 1
Scheme 1. Synthesis of α-Substituted Naphthyl Analogues
Reagents and conditions: (a) 1-naphthyl-MgBr, ether, rt; (b) Aq HCl; (c) LAH, THF, rt; (d) Ms2O, DIEA, DCM, 0 °C; (e) ethyl isonipecotate, rt; (f) aq NaOH, EtOH, THF; (g) piperonylamine, EDCI, HOBt, DIEA, rt.
Scheme 2
Scheme 2. Synthesis of α-Hydroxymethyl Analogue 1b
Reagents and conditions: (a) LAH, THF, rt; (b) TBSCl, imidazole, ether, rt; (c) Ms2O, DIEA, DCM, rt; (d) ethyl isonipecotate, rt; (e) aq NaOH, EtOH, 40 °C; (f) piperonylamine, EDCI, HOBt, DIEA, rt; (g) CsF, aq ACN, rt.
Scheme 3
Scheme 3. Synthesis of α-Phenylmethyl Analogue 1d
Reagents and conditions: (a) BnMgCl, ether, rt; (b) 1 M HCl, ether, 90 °C; (c) CH3ONH2, pyridine, rt; then BH3–THF, 80 °C; (d) dimethyl 2,2-bis((1,3-dioxolan-2-yl)methyl)malonate, HCl/THF; (e) 20, rt, 20 h; (f) H2, Pd/C, 40 psi, rt; (g) NaCN, DMF, 145 °C; (h) 1 M aq NaOH, EtOH, 60 °C; (i) piperonylamine, EDCI, HOBt, DIEA, rt.
Scheme 4
Scheme 4. General Synthesis of Amide Analogues
Reagents and conditions: (a) RNH2, EDCI or HATU, DIEA.
Scheme 5
Scheme 5. Synthesis of Quinolinyl- and Isoquinolinylamides
Reagents and conditions: (a) MeMgCl, THF, −78 °C; (b) Ms2O, DIEA, DCM; (c) ethyl isonipecotate, DCM, rt; (d) 1 M NaOH, MeOH; (e) EDCI, HOBt, DIEA, 3-fluorobenzylamine, THF.
Scheme 6
Scheme 6. Synthesis of Conformationally Restricted Analogue 7
Reagents and conditions: (a) NaBH3CN, NH4OAc, iPrOH, reflux, 44 h; (b) dimethyl 2,2-bis((1,3-dioxolan-2-yl)methyl)malonate, HCl/THF; (c) 30, NaHCO3, rt, 72 h ; (d) H2, PtO2, EA, 40 psi, 5 h; (e) NaCN, DMF, reflux, 16 h; (f) aq LiOH, THF/MeOH, rt; (g) 3-fluorobenzylamine, EDCI, HOBt, DIEA, rt, 16 h.
Figure 2
Figure 2
Chemical structure of compound 7. The conformationally restricted analogue 7 was designed to lock the conformation of compound 3k to the conformation observed in the X-ray crystal structure of SARS-CoV PLpro bound to 15g.
Figure 3
Figure 3
X-ray crystal structures of SARS-CoV PLpro in complex with 3k and 3j. Stereoviews of SARS-CoV PLpro (blue ribbon representation and gray surfaces) in complex with 3k (orange ball and sticks) are shown in (a) and (c), and SARS-CoV PLpro (cyan ribbon representation and gray surface) in complex with 3j (pink ball and sticks) are shown in (b) and (d). The corresponding FoFc electron density omit maps (inhibitor atoms omitted) contoured at 3σ are shown as gray mesh. Important amino acids for inhibitor binding are shown, and the H-bonds between inhibitor atoms and amino acid residues are depicted as dotted lines. A superimposition of SARS-CoV PLpro–3k and PLpro–3j complexes is shown in (e) with conserved water molecules displayed as blue and cyan spheres for the 3k– and 3j– complexes, respectively. A superimposition of SARS-CoV PLpro–15g complex (SARS-CoV PLpro displayed as a gray ribbon and 15g displayed as gray balls and sticks, pdb:3MJ5) with SARS-CoV PLpro–3k and PLpro–3j complex is shown in (f).

References

    1. Summary Table of SARS Cases by Country, 1 November 2002–7 August 2003. WHO: Geneva, August 15, 2003; http://www.who.int/csr/sars/country/2003_08_15/en/.
    1. van Boheemen S.; Zaki A. M.; Bestebroer T. M.; de Graaf M.; Victor S.; Osterhaus A. D.; Haagmans B. L.; Fouchier R. A.. Genomic Analysis for a Newly Isolated Human Betacoronavirus Lineage 2C. Submitted Sep 26, 2012.
    2. Bermingham A.; Chand M.; Brown C.; Aarons E.; Tong C.; Langrish C.; Hoschler K.; Brown K.; Galiano M.; Myers R.; Pebody R.; Green H.; Boddington N.; Gopal R.; Price N.; Newsholme W.; Drosten C.; Fouchier R.; Zambon M. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Eurosurveillance 2012, 1740pii=20290. - PubMed
    3. Pebody R. G.; Chand M. A.; Thomas H. L.; Green H. K.; Boddington N. L.; Carvalho C.; Brown C. S.; Anderson S. R.; Rooney C.; Crawley-Boevey E.; Irwin D. J.; Aarons E.; Tong C.; Newsholme W.; Price N.; Langrish C.; Tucker D.; Zhao H.; Phin N.; Crofts J.; Bermingham A.; Gilgunn-Jones E.; Brown K. E.; Evans B.; Catchpole M.; Watson J. M. The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012. Eurosurveillance 2012, 174020292. - PubMed
    1. de Groot R. J.; Baker S. C.; Baric R. S.; Brown C. S.; Drosten C.; Enjuanes L.; Fouchier R. A.; Galiano M.; Gorbalenya A. E.; Memish Z.; Perlman S.; Poon L. L.; Snijder E. J.; Stephens G. M.; Woo P. C.; Zaki A. M.; Zambon M.; Ziebuhr J. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. J. Virol. 2013, 87, 7790–7792. - PMC - PubMed
    1. Kindler E.; Jonsdottir H. R.; Muth D.; Hamming O. J.; Hartmann R.; Rodriguez R.; Geffers R.; Fouchier R. A.; Drosten C.; Muller M. A.; Dijkman R.; Thiel V. Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic Potential. mBio 2013, 41e00611-12. - PMC - PubMed
    1. van Boheemen S.; de Graaf M.; Lauber C.; Bestebroer T. M.; Raj V. S.; Zaki A. M.; Osterhaus A. D.; Haagmans B. L.; Gorbalenya A. E.; Snijder E. J.; Fouchier R. A. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 2012, 36e00473-12. - PMC - PubMed

Publication types

MeSH terms